Application progress and clinical value of circulating tumor DNA detection technologies in monitoring minimal residual disease in esophageal cancer
- VernacularTitle:循环肿瘤DNA检测技术在食管癌微小残留病灶监测中的应用进展及临床价值
- Author:
Xintian SUN
1
,
2
,
3
,
4
;
Xiaokang ZHU
1
,
2
;
Sixiang ZHOU
3
,
4
;
Qi DENG
3
,
4
;
An ZHANG
3
,
4
;
Zhicheng HU
3
,
4
;
Weirun MIN
2
,
3
;
Yunjiu GOU
3
,
4
;
Gongjian ZHU
1
;
Yanlong LI
2
Author Information
1. Department of Thoracic Surgery, Gansu Hospital of Sun Yat-sen University Cancer Center (Gansu Cancer Hospital), Lanzhou, 730000, P. R. China
2. Department of Cardiothoracic Surgery, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, 730000, P. R. China
3. The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou, 730000, P. R. China
4. Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, 730000, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
circulating tumor DNA;
minimal residual disease;
liquid biopsy;
molecular diagnostic techniques;
treatment monitoring;
prognosis
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(11):1849-1860
- CountryChina
- Language:Chinese
-
Abstract:
As a core biomarker of non-invasive liquid biopsy, circulating tumor DNA (ctDNA) provides a breakthrough approach for minimal residual disease (MRD) monitoring in esophageal cancer. Esophageal cancer is clinically characterized by strong invasiveness, high postoperative recurrence rate, and poor prognosis. Traditional imaging and histopathological examinations are difficult to meet the clinical demand for accurate MRD identification due to limitations such as insufficient sensitivity and high invasiveness. This paper systematically reviews the biological basis and technical advances of ctDNA detection, focusing on the advantages and clinical application scenarios of core technologies including digital polymerase chain reaction, next-generation sequencing, and methylation detection. It further analyzes the core clinical value of ctDNA in esophageal cancer MRD monitoring, covering key directions such as early recurrence warning, dynamic evaluation of treatment efficacy, and optimization of individualized treatment strategies. Meanwhile, the main challenges currently faced, including insufficient technical standardization, interference from tumor heterogeneity, and lag in clinical translation, are discussed, and future development trends such as multi-omics integration and artificial intelligence-assisted diagnosis are prospected. This review aims to provide an academic reference for the precise clinical management of esophageal cancer MRD, promote the standardized application and translation of ctDNA technology in clinical practice of cardiothoracic surgery, and ultimately improve the survival prognosis of patients.